High materiality7/10
Tarsus Pharmaceuticals price target raised to $100 from $97 at Oppenheimer
Why it may matterVerify against the original reporting
Analyst target increase implies continued upside expectations and favorable risk-reward.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Oppenheimer raises price target to $100; current price is $69.46, suggesting a substantial upside potential.
- Oppenheimer raises PT to $100; current price $69.46
Key facts
- 01
Target: $100
- 02
Posted price: $69.46
- 03
Analyst firm: Oppenheimer
- 04
Analyst: Mazahir Alimohamed
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.